Related Experiment Video
Updated: Aug 5, 2026
12:31
In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
Integrating Optical Genome Mapping into the Genetic Diagnostic Algorithm: Clinical Utility in Unresolved Autosomal
Cytogenetic and Genome Research
|July 31, 2026
Summary
Optical genome mapping (OGM) aids in diagnosing genetic disorders by detecting structural variations (SVs) missed by exome sequencing. This technology shows promise for identifying the genetic causes of unexplained inherited diseases.
Area of Science:
- Genomics
- Genetic Diagnostics
- Molecular Biology
Background:
- Monogenic disorders require precise genetic identification for effective clinical management.
- Exome sequencing (ES) often fails to detect complex structural variations (SVs), leaving diagnoses incomplete in 30-60% of cases.
- Optical genome mapping (OGM) offers high-resolution detection of cryptic SVs missed by standard methods.
Purpose of the Study:
- To assess the clinical utility of integrating OGM into diagnostic workflows for unresolved monogenic diseases.
- To evaluate OGM's ability to identify genetic variants missed by conventional diagnostic techniques.
Main Methods:
- OGM was applied to a subset of 7 patients with unresolved genetic disorders after negative or inconclusive exome sequencing (ES) results.
- Patients were selected from a larger cohort of 1,257 individuals with suspected genetic conditions.
Main Results:
- OGM identified potential causative structural variations (SVs) in two cases, including an intronic insertion in TTLL5 and a deletion near NMNAT1.
- These candidate SVs were previously undetected by standard diagnostic testing.
- Parental segregation analysis is pending to confirm the identified SVs.
Conclusions:
- OGM demonstrates potential value in uncovering the genetic basis of autosomal recessive disorders, addressing the 'missing heritability' problem.
- As a complementary tool to exome sequencing, OGM may help resolve complex genetic cases.
- Further research with larger patient cohorts and functional studies is necessary to fully establish OGM's clinical utility.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:46Genetic Screens
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...